Florian Schubert1, Ralf Mekle1, Simone Kühn2, Jürgen Gallinat3, and Bernd Ittermann1
1Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany, 2MPI for Human Development, Berlin, Germany, 3Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Synopsis
Since disturbed amygdala
function is linked to psychiatric conditions insight into its biochemistry,
particularly the neurotransmitters, is required. We combined the SPECIAL MRS sequence
with FAST(EST)MAP implementation, corrections for frequency
drift, relaxation, CSF volume, and a basis set including a measured
macromolecule spectrum for quantification of metabolites in the amygdala in 20
volunteers at 3T. Beyond quantification
of the three main metabolites plus myo-inositol with excellent precision, for
the first time glutamate was determined reliably and separately from glutamine.
Using a basis set without macromolecules introduced a systematic overestimation
of concentrations. Glutamine and glutathione was quantifiable only
in a subset of spectra.Introduction
The amygdala plays a key
role in emotional learning and emotion processing. Since disturbed amygdala
function has been linked to psychiatric conditions such as anxiety, autism and
major depression, insight into its biochemistry, particularly the neurotransmitter
levels, is highly desirable to improve the understanding of the pathophysiology
of these disorders
1. The small size of the amygdala and its difficult
position regarding field homogenization often lead to low signal-to-noise ratio
(SNR) and poor spectral resolution, hampering MRS-based neurochemical profiling in
vivo. Thus, previous MRS studies of the amygdala did not achieve separation of
glutamate (Glu) and glutamine (Gln) nor an estimation of glutathione (GSH), all
metabolites of utter relevance in the above context. We combined the spin echo
full intensity acquired localized (SPECIAL)
2 technique with an
optimized shimming protocol, carefully selected postprocessing steps and data
analysis including a basis set with a measured macromolecule (MM) spectrum for quantification
of metabolites in the human amygdala, including glutamatergic metabolites
and GSH.
Methods
Twenty
healthy volunteers (34.1 ± 8.7 years, 14 female) participated in the study. MR
measurements were performed on a 3T Verio scanner (Siemens Healthcare,
Erlangen, Germany) using a quadrature transmit-receive head coil (Rapid
Biomedical, Rimpar, Germany). Subsequent to MPRAGE imaging a voxel of 15 x 15 x
15 mm
3 (
figure) was carefully placed on the left amygdala using the hippocampal
head as a landmark and avoiding adjacent cerebrospinal fluid (CSF) and white
matter. All first and second order shims were adjusted using optimized FAST(EST)MAP
3;
when the water linewidth (full width at half maximum) after shimming was larger
than 11 Hz, shimming was repeated. MR spectra were then acquired using SPECIAL
with TR = 3 s, TE = 6 ms, 256 averages and acquisition time 1024 ms. Both
metabolite and unsuppressed water raw data were processed using in-house
software written in MATLAB, applying the SPECIAL add/subtract scheme, frequency
drift correction and averaging. Resulting spectra were analyzed using LCModel
with a simulated basis set containing 18 metabolites and, to improve the
accuracy of the analysis
4, a measured MM spectrum (averaged from
five healthy volunteers). Metabolite amplitudes were referenced to an
unsuppressed water scan. Concentrations were corrected for relaxation using measured
and literature values for T1 and T2, and for the amount of CSF in the voxels deduced
from the segmented T1-weighted images using SPM8
5.
Results
In good
agreement with previous studies
6,7, the mean fractional volumes (±
SD) of the amygdala voxel were 0.861 ± 0.027 gray matter, 0.071 ± 0.024 white
matter and 0.068 ± 0.024 CSF. The mean linewidth (± SD) of the water signal
after shimming was (8.1 ± 1.5) Hz; no water spectrum had a linewidth above 10.7
Hz. Frequency drift correction improved the SNR by up to 23 % (mean 9.6 %). The
quality of the resulting metabolite spectra is exemplified in the figure, which
includes the overall fit and the fit
results for the metabolites of interest. The table shows the metabolite
concentrations and corresponding Cramér-Rao lower bounds (CRLB). None of the
individual CRLB for total N-acetylaspartate, creatine and choline (tNAA, tCr,
tCho), myo-inositol (Ins) and, most importantly, Glu exceeded 11 %. Some
individual Gln and GSH values had CRLB above 30 % and were excluded. Repeating,
for comparison, the analysis without measured MM in the basis set, i.e. with
the MM simulated by LCModel, resulted in higher metabolite concentrations,
perhaps due to systematic overestimation, thus demonstrating the importance of
this modification.
Discussion and conclusion
A combination of a carefully executed shimming approach with very short
echo time spectroscopy at 3 T on the acquisition side with data processing
using frequency drift correction and LCModel fitting with measured MM spectra
as prior knowledge proved a successful approach to assess integral parts of the
neurochemical profile in a brain region as difficult to investigate as the
amygdala. Beyond quantification of the three main metabolites plus myo-inositol
with excellent precision, for the first time glutamate was determined reliably and
separately from glutamine. An attempt to use a basis set without macromolecules
introduced a systematic bias into the analysis (possibly overestimated
concentrations). Due to low SNR, quantification of glutamine and glutathione was
not possible in all spectral datasets. As might be expected, the choice of the MM
approach strongly influenced the analytical precision for these
low-concentrated metabolites. Further improvement should be achievable by using
higher order shimming to enhance spectral dispersion. The devised method may
help to elucidate metabolic alterations in the amygdala in psychiatric
disorders.
Acknowledgements
No acknowledgement found.References
1. Nacewicz BM, et al. Neuroimage 2012;59:2548–59.
2. Mlynárik V, et al. Magn Reson Med 2006;56:965–70.
3. Gruetter R. Magn Reson Med 1993;29:804–11.
4. Cudalbu C, et al. J Alzheimers Dis 2012;31:S101–15.
5. http://www.fil.ion.ucl.ac.uk/spm/software/spm8.
6. Hoerst M, et al. Biol Psychiatry 2010;67:399–405.
7. Page L, et al. Am J Psychiatry 2006;163:2189–92.